Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA

Not available.

[1]  J. Cowan,et al.  Outcomes of patients with multiple myeloma harboring chromosome 1q gain/amplification in the era of modern therapy , 2021, Annals of Hematology.

[2]  H. van de Velde,et al.  Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies , 2021, Expert review of hematology.

[3]  M. Dimopoulos,et al.  Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial , 2021, The Lancet.

[4]  H. van de Velde,et al.  Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics , 2021, British journal of haematology.

[5]  A. Oriol,et al.  Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: IKEMA subgroup analysis , 2021, European journal of haematology.

[6]  I. Hanamura.  Gain/Amplification of Chromosome Arm 1q21 in Multiple Myeloma , 2021, Cancers.

[7]  M. Boccadoro,et al.  Impact of Gain and Amplification of 1q in Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Based Treatment in the Forte Trial , 2020 .

[8]  D. Wiederschain,et al.  Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells , 2020, Frontiers in Immunology.

[9]  E. Tian,et al.  Daratumumab in high‐risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome , 2019, British journal of haematology.

[10]  M. Beksac,et al.  Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study , 2019, The Lancet.

[11]  P. Richardson,et al.  CD38 antibodies in multiple myeloma: back to the future. , 2018, Blood.

[12]  P. Sonneveld,et al.  CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. , 2016, Blood.

[13]  M. Dimopoulos,et al.  Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. , 2011, Blood.

[14]  Yongsheng Huang,et al.  Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. , 2006, Blood.

[15]  V. Teplan,et al.  [A new method to estimate glomerular filtration rate based on serum concentration of creatinine, urea and albumin (MDRD, Modification of Diet in Renal Disease)]. , 2004, Vnitrni lekarstvi.